Cancer cells and embryonic tissues share a number of cellular and molecular properties,
suggesting that induced pluripotent stem cells (iPSCs) may be harnessed to elicit anti-tumor …

The history of immunizing with embryonic materials to generate an antitumor immune
response dates back to a century ago. The premise is that cancer cells share the expression …

Over a century ago, it was reported that immunization with embryonic/fetal tissue could lead
to the rejection of transplanted tumors in animals. Subsequent studies demonstrated that …

Induced pluripotent stem cells (iPSCs) are mainly characterized by their unlimited
proliferation abilities and potential to develop into almost any cell type. The creation of this …

Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors
into immunosuppressed mice, preventing an assessment on the immunologic interactions …

Previous reports showed that mouse vaccination with pluripotent stem cells (PSCs) induces
durable anti-tumor immune responses via T cell recognition of some elusive oncofetal …

Abstract Introduction Pluripotent stem cells (PSCs) are promising tools for modern
regenerative medicine applications because of their stemness properties, which include …

Current approaches to adoptive T-cell therapy are limited by the difficulty of obtaining
sufficient numbers of T cells against targeted antigens with useful in vivo characteristics …

Until now, three types of well‐recognized cancer treatments have been developed, ie,
surgery, chemotherapy, and radiotherapy; these either remove or directly attack the cancer …

Induced pluripotent stem cells (iPSCs) hold great promise for autologous cell therapies, but
significant roadblocks remain to translating iPSCs to the bedside. For example, concerns …